In the powder form, this product is stored at 2-8°C. The material is soluble at 2 mg/mL in DMSO. The stability of this product in solution has not been determined. Other sources indicate that aqueous solutions should be prepared fresh daily. This information has not been validated.
SML2283
Lenalidomide
≥98% (HPLC), powder, cereblon binder
Synonym(s):
Lenalidomide, 1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole, 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidin-2,6-dione, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CC 5013, CC-5013
Sign In to View Organizational & Contract Pricing.
About This Item
Empirical Formula (Hill Notation):
C13H13N3O3
CAS Number:
Molecular Weight:
259.26
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Skip To
Product Name
Lenalidomide, ≥98% (HPLC)
InChI
1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
SMILES string
O=C1N(C2CCC(NC2=O)=O)CC3=C1C=CC=C3N
InChI key
GOTYRUGSSMKFNF-UHFFFAOYSA-N
ligand
lenalidomide
assay
≥98% (HPLC)
form
powder
reaction suitability
reagent type: ligand
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Looking for similar products? Visit Product Comparison Guide
1 of 4
This Item | 901558 | P0018 | T144 |
|---|---|---|---|
| assay ≥98% (HPLC) | assay ≥95% | assay ≥98% (HPLC) | assay ≥98% |
| form powder | form powder | form powder | form powder |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. - |
| solubility DMSO: 2 mg/mL, clear | solubility - | solubility DMSO: ≥14 mg/mL | solubility DMSO: 20 mg/mL, clear |
| color white to beige | color - | color yellow | color white |
| ligand lenalidomide | ligand lenalidomide | ligand pomalidomide | ligand thalidomide |
Biochem/physiol Actions
Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent that is approved drug for treatment of multiple myeloma. Apparently Lenalidomide is a ligand of ubiquitin E3 ligase cereblon that induces the enzyme to degrade the Ikaros transcription factors IKAROS family zinc finger 1 (IKZF1) and IKZF3. Lenalidomide possess pleiotropic antitumor effects.[1] It is used in the treatment of 5q-deletion associated myelodysplastic syndrome (del(5q)-MDS).[2]
related product
Product No.
Description
Pricing
signalword
Danger
hcodes
Hazard Classifications
Repr. 1B - STOT RE 2
target_organs
Blood
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuan Xiao Zhu et al.
Blood, 118(18), 4771-4779 (2011-08-24)
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the antimyeloma activity of
Hila Shaim et al.
Frontiers in immunology, 8, 1773-1773 (2018-01-31)
Chronic lymphocytic leukemia (CLL) cells possess regulatory functions comparable to those of normal B10 cells, a regulatory B cell subset that suppresses effector T-cell function through STAT3-mediated IL-10 production. However, the mechanisms governing IL-10 production by CLL cells are not
Georg Petzold et al.
Nature, 532(7597), 127-130 (2016-02-26)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies. IMiDs bind CRBN, the substrate receptor of the CUL4-RBX1-DDB1-CRBN (also known as CRL4(CRBN)) E3 ubiquitin ligase, and inhibit ubiquitination of endogenous
Li Du et al.
Cancer gene therapy (2022-03-27)
Despite the potent effect of lenalidomide (Len) in multiple myeloma (MM) treatment, patients develop Len resistance leading to progressive disease, demanding an urgent need to investigate the mechanisms mediating Len resistance. Our study identified SUMOylation as a potential mechanism regulating
Amanda C Ritter et al.
Comparative medicine, 73(2), 153-172 (2023-03-28)
Mouse kidney parvovirus (MKPV) causes inclusion body nephropathy in severely immunocompromised mice and renal interstitial inflammation in immunocompetent mice. Here we sought to determine the effects of MKPV on pre-clinical murine models that depend on renal function. To assess the
-
What are the preparation and storage instructions for Lenalidomide?
1 answer-
Helpful?
-
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service